GlassScriptPhysician profile
Allyson S Gilstrap
NPI 1679618490
$5,735.83
in general payments reported to CMS, 2019-2025
33 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $117 · 2021: $1,164 · 2022: $859 · 2023: $1,117 · 2024: $1,155 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,270.15 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $586.74 | 2021-2025 | |
| Lilly USA, LLC | $495.02 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $464.87 | 2021-2025 | |
| Glaxosmithkline, LLC. | $386.64 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $241.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $225.78 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Shield Therapeutics INC | $223.44 | 2022-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.50 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $194.30 | 2021-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.61 | 2022-2025 | Jardiance |
| Amgen INC. | $132.49 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Astellas Pharma US INC | $125.06 | 2021 | |
| Sumitomo Pharma America, INC. | $116.41 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $96.61 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $96.44 | 2025 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Tolmar, INC. | $90.19 | 2024-2025 | Jatenzo |
| Phathom Pharmaceuticals, INC. | $78.02 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $73.54 | 2021-2023 | Nexletol |
| Amarin Pharma, INC. | $62.52 | 2021-2022 | |
| Lundbeck LLC | $51.99 | 2021-2023 | Rexulti |
| Antares Pharma, INC. | $47.54 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Halozyme INC | $45.77 | 2023 | |
| Currax Pharmaceuticals LLC | $45.62 | 2024-2025 | Contrave, Onzetra Xsail |
| Dexcom, INC. | $44.59 | 2024-2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $35.89 | 2022 | |
| Merck Sharp & Dohme LLC | $33.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.90 | 2021 | |
| Biogen, INC. | $22.18 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.65 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $15.82 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.09 | 2021 | |
| Axsome Therapeutics, INC. | $9.64 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Gilstrap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.